# Cognitive Impairment Related to Atrial Fibrillation Prevention Trial

Study · id `cardio:ct-nct01994265` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01994265](<https://clinicaltrials.gov/study/NCT01994265>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01994265

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT01994265. Randomized; single masking; primary purpose prevention. Start 2014-11-07 (registry gives no type); primary completion 2021-03-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT01994265, source copy `cardio:ctgov-nct01994265-2021-09-29`, retrieved 2026-10-26)
- Start date: 2014-11-07 (registry gives no type) (ClinicalTrials.gov record NCT01994265, source copy `cardio:ctgov-nct01994265-2021-09-29`, retrieved 2026-10-26)
- Primary completion: 2021-03-09 (actual) (ClinicalTrials.gov record NCT01994265, source copy `cardio:ctgov-nct01994265-2021-09-29`, retrieved 2026-10-26)
- Completion: 2021-03-09 (actual) (ClinicalTrials.gov record NCT01994265, source copy `cardio:ctgov-nct01994265-2021-09-29`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT01994265, source copy `cardio:ctgov-nct01994265-2021-09-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01994265-2021-09-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
- Acronym: GIRAF
- Condition: Atrial Fibrillation
- Intervention (Drug): Warfarin
- Intervention (Drug): Dabigatran
- Lead sponsor: University of Sao Paulo
- Lead sponsor class: OTHER
- Collaborator: Federal University of Minas Gerais
- Collaborator class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry intervention name matches this record: Dabigatran (`cardio:dabigatran`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo (`cardio:org-university-of-sao-paulo`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial (`cardio:pubmed-36284318`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8e3fa6c545f29834200e0d07caba238224b45fc4b8b0d67cf1e2c9bf85e33102
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
